Clinical trials: Progression-Free Survival
Metastatic Breast Cancer
Dose Escalation of POL6326 in Combination With Eribulin in Patients With Metastatic Breast Cancer
POL6326 will be given by i.v. infusion over 2 hours. Treatment will occur on days prior to, on the day of and on days after treatment with eribulin. Different doses and dosing frequencies will be investigated
- Trial name
- NCT01837095
- Testing
- POL6326
- Where
- 12 sites in United States, Spain
- Volunteers
- 54 people
- Sponsor
- Polyphor Ltd.
Advanced Malignancy, Advanced Solid Cancers
ADCX-020 for the Treatment of Patients With Locally Advanced or Metastatic Cancers
The purpose of this first-in-human study is to explore the safety, pharmacokinetics and effects of the study drug ADCX-020 in patients with advanced and metastatic solid tumors.
- Conditions
- Advanced Malignancy, Advanced Solid Cancers, Metastatic Solid Tumors
- Trial name
- NCT07238075
- Testing
- ADCX-020
- Where
- 9 sites in Australia, Spain
- Volunteers
- 290 people
- Sponsor
- Adcytherix SAS
Liver Cancer
A Study of Tarceva (Erlotinib) and Avastin (Bevacizumab) in Patients With Advanced or Metastatic Liver Cancer.
This single arm study evaluated the efficacy and safety of a combination of Tarceva and Avastin in patients with advanced or metastatic liver cancer.
- Trial name
- NCT00605722
- Testing
- bevacizumab (Avastin), erlotinib (Tarceva)
- Where
- 6 sites in Philippines, South Korea and 1 more
- Volunteers
- 51 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer
A Real-world Study of Indian Patients With Advanced Breast Cancer Treated With Ribociclib
The aim of this study was to assess the effectiveness, safety, and tolerability of ribociclib in Indian women with hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-) advanced breast…
- Trial name
- RESONATE (NCT07363434)
- Where
- United States
- Volunteers
- 335 people
- Sponsor
- Novartis Pharmaceuticals